Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Price Crosses Below 200 Day Moving Average - Should You Sell?

Key Points

• Oramed Pharmaceuticals shares fell below their 200-day moving average, trading as low as $4.00 versus the $4.03 average, while the 50-day average stood at $4.55.
• Despite the technical weakness, recent research firms upgraded the stock to “Buy,” and the company has an average analyst rating of “Buy.”
• The company reported a quarterly loss of $0.09 per share, missing the $0.43 consensus estimate, while its CFO and COO sold shares under pre-arranged Rule 10b5-1 plans.

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Get Free Report) shares crossed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $4.03 and traded as low as $4.00. Oramed Pharmaceuticals shares last traded at $4.00, with a volume of 97,260 shares changing hands.

Analyst Upgrades and Downgrades

ORMP has been the topic of several research reports. Wall Street Zen raised Oramed Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday, August 15th. Weiss Ratings upgraded Oramed Pharmaceuticals from a "hold (c+)" rating to a "buy (b-)" rating in a report on Friday, October 23rd. One analyst has rated the stock with a Buy rating. Based on data from MarketBeat.com, the company currently has an average rating of "Buy".

Oramed Pharmaceuticals Stock Down 2.7%

The company has a market cap of $166.40 million, a PE ratio of 0.97 and a beta of 1.29. The stock's 50 day moving average is $4.55 and its 200-day moving average is $4.03.

Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) last released its quarterly earnings data on Monday, August 10th. The biotechnology company reported ($0.09) EPS for the quarter, missing the consensus estimate of $0.43 by ($0.52). On average, analysts anticipate that Oramed Pharmaceuticals Inc. will post 1.47 EPS for the current fiscal year.

Insider Activity

In other Oramed Pharmaceuticals news, CFO Avraham Gabay sold 20,000 shares of the company's stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $4.51, for a total transaction of $90,200.00. Following the sale, the chief financial officer directly owned 861,076 shares in the company, valued at $3,883,452.76. This represents a 2.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Joshua Hexter sold 30,000 shares of the company's stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $4.51, for a total value of $135,300.00. Following the sale, the chief operating officer owned 1,328,130 shares in the company, valued at approximately $5,989,866.30. This trade represents a 2.21% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 20.77% of the company's stock.

Hedge Funds Weigh In On Oramed Pharmaceuticals

Several large investors have recently modified their holdings of the stock. Engineers Gate Manager LP bought a new stake in Oramed Pharmaceuticals in the second quarter worth $61,000. Kathmere Capital Management LLC purchased a new position in Oramed Pharmaceuticals during the first quarter worth $51,000. OMERS ADMINISTRATION Corp bought a new position in Oramed Pharmaceuticals during the first quarter valued at $63,000. Bank of New York Mellon Corp bought a new position in Oramed Pharmaceuticals during the second quarter valued at $381,000. Finally, Hillsdale Investment Management Inc. bought a new position in Oramed Pharmaceuticals during the first quarter valued at $331,000. Institutional investors own 12.73% of the company's stock.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc NASDAQ: ORMP is a biopharmaceutical company focused on developing oral formulations of drugs that are typically administered by injection. The company's proprietary Protein Oral Delivery (POD™) technology is designed to protect therapeutic proteins from degradation in the digestive system and facilitate their absorption through the gastrointestinal tract.

Oramed's development programs have primarily focused on oral insulin, including its investigational ORMD-0801 product candidate for the treatment of diabetes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.